Gene-by-environment interactions (G×Es) can provide important biological insights into psychiatric disorders and may consequently have direct clinical implications. In this review, we begin with an overview of the major challenges G×E studies have faced (e.g., difficulties replicating findings and high false discovery rates). In light of these challenges, this review focuses on describing examples in which we might begin to understand G×Es on the molecular, cellular, circuit, and behavioral level and link this interaction to altered risk for the development of psychiatric disorders. We also describe recent studies that utilize a polygenic approach to examine G×Es. Finally, we discuss how gaining a deeper understanding of G×Es may translate into a therapeutic practice with more targeted treatments.


Article metrics loading...

Loading full text...

Full text loading...


Literature Cited

  1. Agnew-Blais J, Danese A. 2016. Childhood maltreatment and unfavourable clinical outcomes in bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry 3:342–49 [Google Scholar]
  2. Albu S, Romanowski CP, Letizia Curzi M, Jakubcakova V, Flachskamm C. et al. 2014. Deficiency of FK506-binding protein (FKBP) 51 alters sleep architecture and recovery sleep responses to stress in mice. J. Sleep Res. 23:176–85 [Google Scholar]
  3. Alemany S, Arias B, Fatjó-Vilas M, Villa H, Moya J. et al. 2014. Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr. Scand. 129:54–62 [Google Scholar]
  4. Alexander N, Klucken T, Koppe G, Osinsky R, Walter B. et al. 2012. Interaction of the serotonin transporter-linked polymorphic region and environmental adversity: increased amygdala-hypothalamus connectivity as a potential mechanism linking neural and endocrine hyperreactivity. Biol. Psychiatry 72:49–56 [Google Scholar]
  5. Alexander N, Kuepper Y, Schmitz A, Osinsky R, Kozyra E, Hennig J. 2009. Gene–environment interactions predict cortisol responses after acute stress: implications for the etiology of depression. Psychoneuroendocrinology 34:1294–303 [Google Scholar]
  6. Almli LM, Duncan R, Feng H, Ghosh D, Binder EB. et al. 2014. Correcting systematic inflation in genetic association tests that consider interaction effects: application to a genome-wide association study of posttraumatic stress disorder. JAMA Psychiatry 71:1392–99 [Google Scholar]
  7. Andréasson S, Engström A, Allebeck P, Rydberg U. 1987. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet 330:1483–86 [Google Scholar]
  8. Antypa N, Drago A, Serretti A. 2013. The role of COMT gene variants in depression: bridging neuropsychological, behavioral and clinical phenotypes. Neurosci. Biobehav. Rev. 37:1597–610 [Google Scholar]
  9. Arloth J, Bogdan R, Weber P, Frishman G, Menke A. et al. 2015. Genetic differences in the immediate transcriptome response to stress predict risk-related brain function and psychiatric disorders. Neuron 86:1189–202 [Google Scholar]
  10. Aschard H, Lutz S, Maus B, Duell EJ, Fingerlin TE. et al. 2012. Challenges and opportunities in genome-wide environmental interaction (GWEI) studies. Hum. Genet. 131:1591–613 [Google Scholar]
  11. Attwood BK, Bourgognon JM, Patel S, Mucha M, Schiavon E. et al. 2011. Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature 473:372–75 [Google Scholar]
  12. Bale TL, Vale WW. 2004. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44:525–57 [Google Scholar]
  13. Baumeister D, Lightman SL, Pariante CM. 2014. The interface of stress and the HPA axis in behavioural phenotypes of mental illness. Curr. Top. Behav. Neurosci. 18:13–24 [Google Scholar]
  14. Belsky J, Bakermans-Kranenburg MJ, Van IJzendoorn MH. 2007. For better and for worse: differential susceptibility to environmental influences. Curr. Dir. Psychol. Sci. 16:300–4 [Google Scholar]
  15. Belsky J, Pluess M. 2009. Beyond diathesis stress: differential susceptibility to environmental influences. Psychol. Bull. 135:885–908 [Google Scholar]
  16. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC. et al. 2008. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 299:1291–305 [Google Scholar]
  17. Binder EB, Nemeroff CB. 2010. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol. Psychiatry 15:574–88 [Google Scholar]
  18. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M. et al. 2004. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36:1319–25 [Google Scholar]
  19. Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP. et al. 2008. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch. Gen. Psychiatry 65:190–200 [Google Scholar]
  20. Brody GH, Beach SRH, Philibert RA, Chen YF, Murry VM. 2009. Prevention effects moderate the association of 5-HTTLPR and youth risk behavior initiation: gene × environment hypotheses tested via a randomized prevention design. Child Dev 80:645–61 [Google Scholar]
  21. Buchmann AF, Holz N, Boecker R, Blomeyer D, Rietschel M. et al. 2014. Moderating role of FKBP5 genotype in the impact of childhood adversity on cortisol stress response during adulthood. Eur. Neuropsychopharmacol. 24:837–45 [Google Scholar]
  22. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J. et al. 2015. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 47:291–95 [Google Scholar]
  23. Canli T, Qiu M, Omura K, Congdon E, Haas BW. et al. 2006. Neural correlates of epigenesis. PNAS 103:16033–38 [Google Scholar]
  24. Cannon DM, Ichise M, Fromm SJ, Nugent AC, Rollis D. et al. 2006. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol. Psychiatry 60:207–17 [Google Scholar]
  25. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. 2010. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiatry 167:509–27 [Google Scholar]
  26. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R. et al. 2005. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry 57:1117–27 [Google Scholar]
  27. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW. et al. 2003. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386–89 [Google Scholar]
  28. Chan GC, Hinds TR, Impey S, Storm DR. 1998. Hippocampal neurotoxicity of Δ9-tetrahydrocannabinol. J. Neurosci. 18:5322–32 [Google Scholar]
  29. Cheung J, Bryant RA. 2015. FKBP5 risk alleles and the development of intrusive memories. Neurobiol. Learn. Mem. 125:258–64 [Google Scholar]
  30. Cicchetti D, Rogosch FA, Oshri A. 2011. Interactive effects of corticotropin releasing hormone receptor 1, serotonin transporter linked polymorphic region, and child maltreatment on diurnal cortisol regulation and internalizing symptomatology. Dev. Psychopathol. 23:1125–38 [Google Scholar]
  31. Cline JI, Belsky J, Li Z, Melhuish E, Lysenko L. et al. 2015. Take your mind off it: coping style, serotonin transporter linked polymorphic region genotype (5-HTTLPR), and children's internalizing and externalizing problems. Dev. Psychopathol. 27:1129–43 [Google Scholar]
  32. Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S. 2016. Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neurosci. Biobehav. Rev. 64:359–81 [Google Scholar]
  33. Costas J, Sanjuán J, Ramos-Ríos R, Paz E, Agra S. et al. 2011. Interaction between COMT haplotypes and cannabis in schizophrenia: a case-only study in two samples from Spain. Schizophr. Res. 127:22–27 [Google Scholar]
  34. Craddock N, Owen MJ, O'Donovan MC. 2006. The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Mol. Psychiatry 11:446–58 [Google Scholar]
  35. Dannlowski U, Ohrmann P, Bauer J, Deckert J, Hohoff C. et al. 2008. 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression. Neuropsychopharmacology 33:418–24 [Google Scholar]
  36. Dannlowski U, Ohrmann P, Bauer J, Kugel H, Baune BT. et al. 2007. Serotonergic genes modulate amygdala activity in major depression. Genes Brain Behav 6:672–76 [Google Scholar]
  37. Davies TH, Ning YM, Sánchez ER. 2002. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J. Biol. Chem. 277:4597–600 [Google Scholar]
  38. Derkinderen P, Ledent C, Parmentier M, Girault JA. 2001. Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J. Neurochem. 77:957–60 [Google Scholar]
  39. Dick DM, Agrawal A, Keller MC, Adkins A, Aliev F. et al. 2015. Candidate gene-environment interaction research: reflections and recommendations. Perspect. Psychol. Sci. 10:37–59 [Google Scholar]
  40. Downer EJ, Fogarty MP, Campbell VA. 2003. Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons. Br. J. Pharmacol. 140:547–57 [Google Scholar]
  41. Duncan LE, Keller MC. 2011. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am. J. Psychiatry 168:1041–49 [Google Scholar]
  42. Dunn EC, Wiste A, Radmanesh F, Almli LM, Gogarten SM. et al. 2016. Genome-wide association study (GWAS) and genome-wide by environment interaction study (GWEIS) of depressive symptoms in African American and Hispanic/Latina women. Depress. Anxiety 33:265–80 [Google Scholar]
  43. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM. et al. 2001. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. PNAS 98:6917–22 [Google Scholar]
  44. Eley TC, Hudson JL, Creswell C, Tropeano M, Lester KJ. et al. 2012. Therapygenetics: the 5HTTLPR and response to psychological therapy. Mol. Psychiatry 17:236–37 [Google Scholar]
  45. Eley TC, Sugden K, Corsico A, Gregory AM, Sham P. et al. 2004. Gene–environment interaction analysis of serotonin system markers with adolescent depression. Mol. Psychiatry 9:908–15 [Google Scholar]
  46. Fani N, Gutman D, Tone EB, Almli L, Mercer KB. et al. 2013. FKBP5 and attention bias for threat: associations with hippocampal function and shape. JAMA Psychiatry 70:392–400 [Google Scholar]
  47. Fani N, King TZ, Reiser E, Binder EB, Jovanovic T. et al. 2014. FKBP5 genotype and structural integrity of the posterior cingulum. Neuropsychopharmacology 39:1206–13 [Google Scholar]
  48. Fani N, King TZ, Shin J, Srivastava A, Brewster RC. et al. 2016. Structural and functional connectivity in post-traumatic stress disorder: associations with FKBP5. Depress. Anxiety 33:300–7 [Google Scholar]
  49. Fortier E, Noreau A, Lepore F, Boivin M, Pérusse D. et al. 2010. Early impact of 5-HTTLPR polymorphism on the neural correlates of sadness. Neurosci. Lett. 485:261–65 [Google Scholar]
  50. Frankle WG, Narendran R, Huang Y, Hwang DR, Lombardo I. et al. 2005. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biol. Psychiatry 57:1510–16 [Google Scholar]
  51. Funke B, Malhotra AK, Finn CT, Plocik AM, Lake SL. et al. 2005. COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav. Brain Funct. 1:1–19 [Google Scholar]
  52. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS. et al. 2010. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 67:133–38 [Google Scholar]
  53. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. 2009. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr. Serv. 60:1439–45 [Google Scholar]
  54. Investig GENDEP., Investig MARS., Investig STAR*D 2013. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am. J. Psychiatry 170:207–17 [Google Scholar]
  55. Gibb BE, McGeary JE, Beevers CG, Miller IW. 2006. Serotonin transporter (5-HTTLPR) genotype, childhood abuse, and suicide attempts in adult psychiatric inpatients. Suicide Life Threat. Behav. 36:687–93 [Google Scholar]
  56. Grabe HJ, Wittfeld K, Van der Auwera S, Janowitz D, Hegenscheid K. et al. 2016. Effect of the interaction between childhood abuse and rs1360780 of the FKBP5 gene on gray matter volume in a general population sample. Hum. Brain Mapp. 37:1602–13 [Google Scholar]
  57. Grad I, Picard D. 2007. The glucocorticoid responses are shaped by molecular chaperones. Mol. Cell. Endocrinol. 275:2–12 [Google Scholar]
  58. Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J. 2011. Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol. Psychiatry 69:487–94 [Google Scholar]
  59. Hamilton JP, Glover GH, Bagarinao E, Chang C, Mackey S. et al. 2016. Effects of salience-network-node neurofeedback training on affective biases in major depressive disorder. Psychiatry Res. Neuroimaging 249:91–96 [Google Scholar]
  60. Hamilton JP, Gotlib IH. 2008. Neural substrates of increased memory sensitivity for negative stimuli in major depression. Biol. Psychiatry 63:1155–62 [Google Scholar]
  61. Hankin BL, Nederhof E, Oppenheimer CW, Jenness J, Young JF. et al. 2011. Differential susceptibility in youth: evidence that 5-HTTLPR×positive parenting is associated with positive affect ‘for better and worse’. Transl. Psychiatry 1:e44 [Google Scholar]
  62. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS. et al. 2005. A susceptibility gene for affective disorders and the response of the human amygdala. Arch. Gen. Psychiatry 62:146–52 [Google Scholar]
  63. Hartmann J, Wagner KV, Gaali S, Kirschner A, Kozany C. et al. 2015. Pharmacological inhibition of the psychiatric risk factor FKBP51 has anxiolytic properties. J. Neurosci. 35:9007–16 [Google Scholar]
  64. Hartmann J, Wagner KV, Liebl C, Scharf SH, Wang XD. et al. 2012. The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology 62:332–39 [Google Scholar]
  65. Heim C, Bradley B, Mletzko T, Deveau TC, Musselmann DL. et al. 2009. Effect of childhood trauma on adult depression and neuroendocrine function: sex-specific moderation by CRH receptor 1 gene. Front. Behav. Neurosci. 3:1–10 [Google Scholar]
  66. Hettema JM, An SS, Bukszar J, Van den Oord EJ, Neale MC. et al. 2008. Catechol-O-methyltransferase contributes to genetic susceptibility shared among anxiety spectrum phenotypes. Biol. Psychiatry 64:302–10 [Google Scholar]
  67. Hettema JM, Chen X, Sun C, Brown TA. 2015. Direct, indirect and pleiotropic effects of candidate genes on internalizing disorder psychopathology. Psychol. Med. 45:2227–36 [Google Scholar]
  68. Hirakawa H, Akiyoshi J, Muronaga M, Tanaka Y, Ishitobi Y. et al. 2016. FKBP5 is associated with amygdala volume in the human brain and mood state: a voxel-based morphometry (VBM) study. Int. J. Psychiatry Clin. Pract. 20:1–10 [Google Scholar]
  69. Ho BC, Wassink TH, Ziebell S, Andreasen NC. 2011. Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr. Res. 128:66–75 [Google Scholar]
  70. Holsboer F. 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477–501 [Google Scholar]
  71. Holtzheimer PE, Mayberg HS. 2011. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 34:1–9 [Google Scholar]
  72. Holz NE, Buchmann AF, Boecker R, Blomeyer D, Baumeister S. et al. 2015. Role of FKBP5 in emotion processing: results on amygdala activity, connectivity and volume. Brain Struct. Funct. 220:1355–68 [Google Scholar]
  73. Hsu DT, Mickey BJ, Langenecker SA, Heitzeg MM, Love TM. et al. 2012. Variation in the corticotropin-releasing hormone receptor 1 (CRHR1) gene influences fMRI signal responses during emotional stimulus processing. J. Neurosci. 32:3253–60 [Google Scholar]
  74. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J. et al. 2006. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 78:815–26 [Google Scholar]
  75. Hygen BW, Belsky J, Stenseng F, Lydersen S, Guzey IC, Wichstrom L. 2015. Child exposure to serious life events, COMT, and aggression: testing differential susceptibility theory. Dev. Psychol. 51:1098–104 [Google Scholar]
  76. Ising M, Depping AM, Siebertz A, Lucae S, Unschuld PG. et al. 2008. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur. J. Neurosc. 28:389–98 [Google Scholar]
  77. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M. et al. 2009. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 66:966–75 [Google Scholar]
  78. Johnstone JM, Luty SE, Carter JD, Mulder RT, Frampton C, Joyce PR. 2009. Childhood neglect and abuse as predictors of antidepressant response in adult depression. Depress. Anxiety 26:711–17 [Google Scholar]
  79. Kapur S. 2003. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 160:13–23 [Google Scholar]
  80. Karg K, Burmeister M, Shedden K, Sen S. 2011. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch. Gen. Psychiatry 68:444–54 [Google Scholar]
  81. Keers R, Aitchison KJ. 2011. Pharmacogenetics of antidepressant response. Expert Rev. Neurother. 11:101–25 [Google Scholar]
  82. Keers R, Uher R. 2012. Gene–environment interaction in major depression and antidepressant treatment response. Curr. Psychiatry Rep. 14:129–37 [Google Scholar]
  83. Keers R, Uher R, Huezo-Diaz P, Smith R, Jaffee S. et al. 2011. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J 11:138–45 [Google Scholar]
  84. Kilpatrick DG, Koenen KC, Ruggiero KJ, Acierno R, Galea S. et al. 2007. The serotonin transporter genotype and social support and moderation of posttraumatic stress disorder and depression in hurricane-exposed adults. Am. J. Psychiatry 164:1693–99 [Google Scholar]
  85. Klengel T, Binder EB. 2015. FKBP5 allele-specific epigenetic modification in gene by environment interaction. Neuropharmacol. Rev. 40:244–46 [Google Scholar]
  86. Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC. et al. 2013. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat. Neurosci. 16:33–41 [Google Scholar]
  87. Knuts I, Esquivel G, Kenis G, Overbeek T, Leibold N. et al. 2014. Therapygenetics: 5-HTTLPR genotype predicts the response to exposure therapy for agoraphobia. Eur. Neuropsychopharmacol. 24:1222–28 [Google Scholar]
  88. Koenen KC, Aiello AE, Bakshis E, Amstadter AB, Ruggiero KJ. et al. 2009. Modification of the association between serotonin transporter genotype and risk of posttraumatic stress disorder in adults by county-level social environment. Am. J. Epidemiol. 169:704–11 [Google Scholar]
  89. Koenen KC, Saxe G, Purcell S, Smoller JW, Bartholomew D. et al. 2005. Polymorphisms in FKBP5 are associated with peritraumatic dissociation in medically injured children. Mol. Psychiatry 10:1058–59 [Google Scholar]
  90. Koob GF. 1999. Corticotropin-releasing factor, norepinephrine, and stress. Biol. Psychiatry 46:1167–80 [Google Scholar]
  91. Kraft P, Aschard H. 2015. Finding the missing gene-environment interactions. Eur. J. Epidemiol. 30:353–55 [Google Scholar]
  92. Kranzler HR, Scott D, Tennen H, Feinn R, Williams C. et al. 2012. The 5-HTTLPR polymorphism moderates the effect of stressful life events on drinking behavior in college students of African descent. Am. J. Med. Genet. B Neuropsychiatr. Genet 159:484–90 [Google Scholar]
  93. Laucht M, Treutlein J, Blomeyer D, Buchmann AF, Schmid B. et al. 2009. Interaction between the 5-HTTLPR serotonin transporter polymorphism and environmental adversity for mood and anxiety psychopathology: evidence from a high-risk community sample of young adults. Int. J. Neuropsychopharmacol. 12:737–47 [Google Scholar]
  94. Lawrie SM, Hall J, McIntosh AM, Cunningham-Owens DG, Johnstone EC. 2008. Neuroimaging and molecular genetics of schizophrenia: pathophysiological advances and therapeutic potential. Brit. J. Pharmacol. 153:S120–24 [Google Scholar]
  95. Lee RS, Sawa A. 2014. Environmental stressors and epigenetic control of the hypothalamic-pituitary-adrenal axis. Neuroendocrinology 100:278–87 [Google Scholar]
  96. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD. et al. 1996. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527–31 [Google Scholar]
  97. Lester KJ, Hudson JL, Tropeano M, Creswell C, Collier DA. et al. 2012. Neurotrophic gene polymorphisms and response to psychological therapy. Transl. Psychiatry 2:e108 [Google Scholar]
  98. Licinio J, O'kirwan F, Irizarry K, Merriman B, Thakur S. et al. 2004. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol. Psychiatry 9:1075–82 [Google Scholar]
  99. Linden DE, Habes I, Johnston SJ, Linden S, Tatineni R. et al. 2012. Real-time self-regulation of emotion networks in patients with depression. PLOS ONE 7:e38115 [Google Scholar]
  100. Liu Y, Garrett ME, Dennis MF, Green KT, Ashley-Koch AE. et al. 2015. An examination of the association between 5-HTTLPR, combat exposure, and PTSD diagnosis among US veterans. PLOS ONE 10:e0119998 [Google Scholar]
  101. Lonsdorf TB, Rück C, Bergström J, Andersson G, Öhman A. et al. 2010. The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. BMC Psychiatry 10:99–107 [Google Scholar]
  102. Maier R, Moser G, Chen GB, Ripke S, Coryell W. et al. 2015. Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder. Am. J. Hum. Genet. 96:283–94 [Google Scholar]
  103. Malone DT, Hill MN, Rubino T. 2010. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br. J. Pharmacol. 160:511–22 [Google Scholar]
  104. Mandelli L, Marino E, Pirovano A, Calati R, Zanardi R. et al. 2009. Interaction between SERTPR and stressful life events on response to antidepressant treatment. Eur. Neuropsychopharmacol. 19:64–67 [Google Scholar]
  105. Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S. et al. 2000. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch. Gen. Psychiatry 57:729–38 [Google Scholar]
  106. Männistö PT, Kaakkola S. 1999. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51:593–628 [Google Scholar]
  107. Mueller A, Strahler J, Armbruster D, Lesch KP, Brocke B, Kirschbaum C. 2012. Genetic contributions to acute autonomic stress responsiveness in children. Int. J. Psychophysiol. 83:302–8 [Google Scholar]
  108. Mullins N, Power RA, Fisher HL, Hanscombe KB, Euesden J. et al. 2016. Polygenic interactions with environmental adversity in the aetiology of major depressive disorder. Psychol. Med. 46:759–70 [Google Scholar]
  109. Munafo MR, Brown SM, Hariri AR. 2008. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol. Psychiatry 63:852–57 [Google Scholar]
  110. Munafo MR, Freimer NB, Ng W, Ophoff R, Veijola J. et al. 2009. 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. Am. J. Med. Genet. B Neuropsychiatr. Genet 150:271–81 [Google Scholar]
  111. Musliner KL, Seifuddin F, Judy JA, Pirooznia M, Goes FS, Zandi PP. 2015. Polygenic risk, stressful life events and depressive symptoms in older adults: a polygenic score analysis. Psychol. Med. 45:1709–20 [Google Scholar]
  112. Nanni V, Uher R, Danese A. 2012. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am. J. Psychiatry 169:141–51 [Google Scholar]
  113. Nemeroff CB. 1989. Clinical significance of psychoneuroendocrinology in psychiatry: focus on the thyroid and adrenal. J. Clin. Psychiatry 50:Suppl. 13–2021–22 [Google Scholar]
  114. Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ. et al. 2003. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. PNAS 100:14293–96 [Google Scholar]
  115. Niesink RJ, van Laar MW. 2013. Does cannabidiol protect against adverse psychological effects of THC. Front. Psychiatry 4:1–8 [Google Scholar]
  116. Nievergelt CM, Maihofer AX, Mustapic M, Yurgil KA, Schork NJ. et al. 2015. Genomic predictors of combat stress vulnerability and resilience in US Marines: a genome-wide association study across multiple ancestries implicates PRTFDC1 as a potential PTSD gene. Psychoneuroendocrinology 51:459–71 [Google Scholar]
  117. Niitsu T, Fabbri C, Bentini F, Serretti A. 2013. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 45:183–94 [Google Scholar]
  118. Novik KL, Nimmrich I, Genc B, Maier S, Piepenbrock C. et al. 2002. Epigenomics: genome-wide study of methylation phenomena. Curr. Issues Mol. Biol. 4:111–28 [Google Scholar]
  119. Ohnishi T, Hashimoto R, Mori T, Nemoto K, Moriguchi Y. et al. 2006. The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. Brain 129:399–410 [Google Scholar]
  120. O'Leary JC. Dharia S, Blair LJ, Brady S, Johnson AG. III, et al. 2011. A new anti-depressive strategy for the elderly: ablation of FKBP5/FKBP51. PLOS ONE 6:e24840 [Google Scholar]
  121. Onwuameze OE, Nam KW, Epping EA, Wassink TH, Ziebell S. et al. 2013. MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol. Med 43:619–31 [Google Scholar]
  122. Ozomaro U, Wahlestedt C, Nemeroff CB. 2013. Personalized medicine in psychiatry: problems and promises. BMC Med 11:132–67 [Google Scholar]
  123. Pazos MR, Nunez E, Benito C, Tolon RM, Romero J. 2005. Functional neuroanatomy of the endocannabinoid system. Pharmacol. Biochem. Behav. 81:239–47 [Google Scholar]
  124. Pérez-Ortiz JM, García-Gutiérrez MS, Navarrete F, Giner S, Manzanares J. 2013. Gene and protein alterations of FKBP5 and glucocorticoid receptor in the amygdala of suicide victims. Psychoneuroendocrinology 38:1251–58 [Google Scholar]
  125. Peyrot WJ, Milaneschi Y, Abdellaoui A, Sullivan PF, Hottenga JJ. et al. 2014. Effect of polygenic risk scores on depression in childhood trauma. Br. J. Psychiatry 205:113–19 [Google Scholar]
  126. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE. et al. 2005. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat. Neurosci. 8:828–34 [Google Scholar]
  127. Pluess M, Belsky J, Way BM, Taylor SE. 2010. 5-HTTLPR moderates effects of current life events on neuroticism: differential susceptibility to environmental influences. Prog. Neuropsychopharmacol. Biol. Psychiatry 34:1070–74 [Google Scholar]
  128. Polanczyk G, Caspi A, Williams B, Price TS, Danese A. et al. 2009. Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension. Arch. Gen. Psychiatry 66:978–85 [Google Scholar]
  129. Porcelli S, Fabbri C, Serretti A. 2012. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur. Neuropsychopharmacol. 22:239–58 [Google Scholar]
  130. Potter E, Sutton S, Donaldson C, Chen R, Perrin M. et al. 1994. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. PNAS 91:8777–81 [Google Scholar]
  131. Powles T, te Poele R, Shamash J, Chaplin T, Propper D. et al. 2005. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105:1214–21 [Google Scholar]
  132. Ripke S, Neale BM, Corvin A, Walters JT, Farh KH. et al. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421–27 [Google Scholar]
  133. Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM. et al. 2013. A mega-analysis of genome-wide association studies for major depressive disorder. Mol. Psychiatry 18:497–511 [Google Scholar]
  134. Risch N, Herrell R, Lehner T, Liang KY, Eaves L. et al. 2009. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 301:2462–71 [Google Scholar]
  135. Roy A, Hu XZ, Janal MN, Goldman D. 2007. Interaction between childhood trauma and serotonin transporter gene variation in suicide. Neuropsychopharmacology 32:2046–52 [Google Scholar]
  136. Rutter M, Moffitt TE, Caspi A. 2006. Gene–environment interplay and psychopathology: multiple varieties but real effects. J. Child Psychol. Psychiatry 47:226–61 [Google Scholar]
  137. Rutter M, Pickles A. 2015. Annual research review: threats to the validity of child psychiatry and psychology. J. Child Psychol. Psychiatry 57:398–416 [Google Scholar]
  138. Sami MB, Rabiner EA, Bhattacharyya S. 2015. Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. Eur. Neuropsychopharmacol. 25:1201–24 [Google Scholar]
  139. Sawamura T, Klengel T, Armario A, Jovanovic T, Norrholm SD. et al. 2016. Dexamethasone treatment leads to enhanced fear extinction and dynamic Fkbp5 regulation in amygdala. Neuropsychopharmacology 41:832–46 [Google Scholar]
  140. Scharf SH, Liebl C, Binder EB, Schmidt MV, Müller MB. 2011. Expression and regulation of the Fkbp5 gene in the adult mouse brain. PLOS ONE 6:e16883 [Google Scholar]
  141. Schubart CD, Van Gastel WA, Breetvelt EJ, Beetz SL, Ophoff RA. et al. 2011. Cannabis use at a young age is associated with psychotic experiences. Psychol. Med. 41:1301–10 [Google Scholar]
  142. Sharma S, Powers A, Bradley B, Ressler KJ. 2016. Gene × environment determinants of stress- and anxiety-related disorders. Annu. Rev. Psychol. 67:239–61 [Google Scholar]
  143. Sharpley CF, Palanisamy SK, Glyde NS, Dillingham PW, Agnew LL. 2014. An update on the interaction between the serotonin transporter promoter variant (5-HTTLPR), stress and depression, plus an exploration of non-confirming findings. Behav. Brain Res. 273:89–105 [Google Scholar]
  144. Shirazi SN, Friedman AR, Kaufer D, Sakhai SA. 2015. Glucocorticoids and the brain: neural mechanisms regulating the stress response. Glucocorticoid Signaling J-C Wang, C Harris 235–52 New York: Springer [Google Scholar]
  145. Sinclair D, Fillman SG, Webster MJ, Weickert CS. 2013. Dysregulation of glucocorticoid receptor co-factors FKBP5, BAG1 and PTGES3 in prefrontal cortex in psychotic illness. Sci. Rep. 3:1–10 [Google Scholar]
  146. Solovieff N, Roberts AL, Ratanatharathorn A, Haloosim M, De Vivo I. et al. 2014. Genetic association analysis of 300 genes identifies a risk haplotype in SLC18A2 for post-traumatic stress disorder in two independent samples. Neuropsychopharmacology 39:1872–79 [Google Scholar]
  147. Starr LR, Hammen C, Conway CC, Raposa E, Brennan PA. 2014. Sensitizing effect of early adversity on depressive reactions to later proximal stress: moderation by polymorphisms in serotonin transporter and corticotropin releasing hormone receptor genes in a 20-year longitudinal study. Dev. Psychopathol. 26:1241–54 [Google Scholar]
  148. Stein MB, Schork NJ, Gelernter J. 2008. Gene-by-environment (serotonin transporter and childhood maltreatment) interaction for anxiety sensitivity, an intermediate phenotype for anxiety disorders. Neuropsychopharmacology 33:312–19 [Google Scholar]
  149. Stoltenberg SF, Anderson C, Nag P, Anagnopoulos C. 2012. Association between the serotonin transporter triallelic genotype and eating problems is moderated by the experience of childhood trauma in women. Int. J. Eat. Disord. 45:492–500 [Google Scholar]
  150. Taylor SE, Way BM, Welch WT, Hilmert CJ, Lehman BJ, Eisenberger NI. 2006. Early family environment, current adversity, the serotonin transporter promoter polymorphism, and depressive symptomatology. Biol. Psychiatry 60:671–76 [Google Scholar]
  151. Thapar A, Langley K, Fowler T, Rice F, Turic D. et al. 2005. Catechol O-methyltransferase gene variant and birth weight predict early-onset antisocial behavior in children with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 62:1275–78 [Google Scholar]
  152. Thomassin H, Flavin M, Espinas ML, Grange T. 2001. Glucocorticoid-induced DNA demethylation and gene memory during development. EMBO J 20:1974–83 [Google Scholar]
  153. Touma C, Gassen NC, Herrmann L, Cheung-Flynn J, Büll DR. et al. 2011. FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior. Biol. Psychiatry 70:928–36 [Google Scholar]
  154. Tozzi L, Carballedo A, Wetterling F, McCarthy H, O'Keane V. et al. 2016. Single-nucleotide polymorphism of the FKBP5 gene and childhood maltreatment as predictors of structural changes in brain areas involved in emotional processing in depression. Neuropsychopharmacology 41:487–97 [Google Scholar]
  155. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D. et al. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163:28–40 [Google Scholar]
  156. Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM, Carpenter LL. 2009. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. Biol. Psychiatry 66:681–85 [Google Scholar]
  157. Uher R, Caspi A, Houts R, Sugden K, Williams B. et al. 2011. Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not single-episode depression: replications and implications for resolving inconsistent results. J. Affect. Disord. 135:56–65 [Google Scholar]
  158. Uher R, McGuffin P. 2008. The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol. Psychiatry 13:131–46 [Google Scholar]
  159. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N. et al. 2010. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 167:555–64 [Google Scholar]
  160. Vale W, Spiess J, Rivier C, Rivier J. 1981. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 213:1394–97 [Google Scholar]
  161. van der Meer D, Hartman CA, Richards J, Bralten JB, Franke B. et al. 2014. The serotonin transporter gene polymorphism 5-HTTLPR moderates the effects of stress on attention-deficit/hyperactivity disorder. J. Child Psychol. Psychiatry 55:1363–71 [Google Scholar]
  162. van Winkel R. 2011. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch. Gen. Psychiatry 68:148–57 [Google Scholar]
  163. Vermeer H, Hendriks-Stegeman BI, van der Burg B, van Buul-Offers SC, Jansen M. 2003. Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J. Clin. Endocrinol. Metab. 88:277–84 [Google Scholar]
  164. Vinkers CH, Van Gastel WA, Schubart CD, Van Eijk KR, Luykx JJ. et al. 2013. The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val158Met polymorphism. Schizophr. Res. 150:303–11 [Google Scholar]
  165. Weber H, Richter J, Straube B, Lueken U, Domschke K. et al. 2016. Allelic variation in CRHR1 predisposes to panic disorder: evidence for biased fear processing. Mol. Psychiatry 21:813–22 [Google Scholar]
  166. White MG, Bogdan R, Fisher PM, Munoz KE, Williamson DE, Hariri AR. 2012. FKBP5 and emotional neglect interact to predict individual differences in amygdala reactivity. Genes Brain Behav 11:869–78 [Google Scholar]
  167. Wochnik GM, Rüegg J, Abel GA, Schmidt U, Holsboer F, Rein T. 2005. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J. Biol. Chem. 280:4609–16 [Google Scholar]
  168. Xie P, Kranzler HR, Poling J, Stein MB, Anton RF. et al. 2009. Interactive effect of stressful life events and the serotonin transporter 5-HTTLPR genotype on posttraumatic stress disorder diagnosis in 2 independent populations. Arch. Gen. Psychiatry 66:1201–9 [Google Scholar]
  169. Young KA, Thompson PM, Cruz DA, Williamson DE, Selemon LD. 2015. BA11 FKBP5 expression levels correlate with dendritic spine density in postmortem PTSD and controls. Neurobiol. Stress 2:67–72 [Google Scholar]
  170. Young KD, Zotev V, Phillips R, Misaki M, Yuan H. et al. 2014. Real-time FMRI neurofeedback training of amygdala activity in patients with major depressive disorder. PLOS ONE 9:e88785 [Google Scholar]
  171. Zammit S, Owen MJ, Evans J, Heron J, Lewis G. 2011. Cannabis, COMT and psychotic experiences. Br. J. Psychiatry 199:380–85 [Google Scholar]
  172. Zammit S, Spurlock G, Williams H, Norton N, Williams N. et al. 2007. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br. J. Psychiatry 191:402–7 [Google Scholar]
  173. Zannas AS, Wiechmann T, Gassen NC, Binder EB. 2016. Gene-stress-epigenetic regulation of FKBP5: clinical and translational implications. Neuropsychopharmacology 41:261–74 [Google Scholar]
  174. Zou YF, Wang F, Feng XL, Li WF, Tao JH. et al. 2010. Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci. Lett. 484:56–61 [Google Scholar]

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error